title: Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.
abstract: Recent data suggest that azacitidine may be beneficial in CMML. We report on 48 CMML-patients treated with azacitidine. Overall response rates were high (70% according to IWG-criteria, including 22% complete responses). Monocyte count and cytogenetics adversely affected survival, whereas age, WHO-type, FAB-type, and spleen size did not. Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p=0.067) and longer OS for azacitidine first-line vs. hydroxyurea first-line (p=0.072, median OS 27.7 vs. 6.2 months). This report reinforces existing evidence that azacitidine is safe and efficacious in both myelodysplastic and myeloproliferative CMML.
authors: 3rd Medical Department with Hematology and Medical Oncology, Hemostasiology, Rheumatology and Infectiology, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Hospital Salzburg, Austria.
authors: Lisa
authors: L
authors: Pleyer
authors: University Hospital, Department of Hematology, Oncology and Clinical Immunology, Düsseldorf, Germany.
authors: Ulrich
authors: U
authors: Germing
authors: Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
authors: Wolfgang R
authors: WR
authors: Sperr
authors: Department for Internal Medicine and Hematology, University Hospital, Graz, Austria.
authors: Werner
authors: W
authors: Linkesch
authors: Department for Internal Medicine IV, Hospital Wels-Grieskirchen, Austria.
authors: Sonja
authors: S
authors: Burgstaller
authors: Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Austria.
authors: Reinhard
authors: R
authors: Stauder
authors: Department of Medicine I, Center of Hematology and Stem Cell Transplantation, Hemostasis and Medical Oncology, Elisabethinen Hospital Linz, Austria.
authors: Michael
authors: M
authors: Girschikofsky
authors: 1st Department of Internal Medicine, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria.
authors: Martin
authors: M
authors: Schreder
authors: IIIrd Medical Department, Hanusch Hospital, Vienna, Austria.
authors: Michael
authors: M
authors: Pfeilstocker
authors: Internal Medicine, Hospital Feldkirch, Austria.
authors: Alois
authors: A
authors: Lang
authors: 5th Medical Department with Oncology und Palliative Medicine, Hietzing, Vienna, Austria.
authors: Thamer
authors: T
authors: Sliwa
authors: Department for Internal Medicine, with Nephrology, Gastroenterology and Hepatology, Hematology and Medical Onkology, Intensive Care Unit, and Rheumatology, Klinikum Klagenfurt am Wörtersee, Pörtschach am Wörthersee, Austria.
authors: Dietmar
authors: D
authors: Geissler
authors: 3rd Medical Department with Hematology and Medical Oncology, Hemostasiology, Rheumatology and Infectiology, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Hospital Salzburg, Austria.
authors: Konstantin
authors: K
authors: Schlick
authors: 3rd Medical Department with Hematology and Medical Oncology, Hemostasiology, Rheumatology and Infectiology, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Hospital Salzburg, Austria.
authors: Gudrun
authors: G
authors: Placher-Sorko
authors: Department for Internal Medicine and Hematology, University Hospital, Graz, Austria.
authors: Georg
authors: G
authors: Theiler
authors: Department for Internal Medicine IV, Hospital Wels-Grieskirchen, Austria.
authors: Josef
authors: J
authors: Thaler
authors: Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Austria.
authors: Martina
authors: M
authors: Mitrovic
authors: Institute of Pathology, Paracelsus Medical University, Salzburg, Austria.
authors: Daniel
authors: D
authors: Neureiter
authors: Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
authors: Peter
authors: P
authors: Valent
authors: 3rd Medical Department with Hematology and Medical Oncology, Hemostasiology, Rheumatology and Infectiology, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Hospital Salzburg, Austria. Electronic address: r.greil@salk.at.
authors: Richard
authors: R
authors: Greil
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D016019:Survival Analysis
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine
keywords: Austrian Azacitidine Registry; Azacitidine; CMML; Chronic myelomonocytic leukemia; Matched-pair analysis